Walleye Capital
SYRE icon

Walleye Capital’s Spyre Therapeutics SYRE Stock Holding History

Walleye Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-243,372
Closed -$7.16M – 5539
2024
Q3 		$7.16M Buy
243,372
+92,552
+61% +$2.58M 0.01% 919
2024
Q2 		$3.55M Buy
150,820
+39,342
+35% +$1.33M 0.01% 1565
2024
Q1 		$4.23M Buy
+111,478
New +$3.23M 0.01% 1419
2022
Q2 		– Sell
-5,424
Closed -$312K – 2710
2022
Q1 		$312K Buy
+5,424
New +$455K 0.01% 1293

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Walleye Capital's SYRE Position: Q4 2024 in Review

Walleye Capital sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 243,372 shares — an estimated $7.16M sold.

Walleye Capital first reported a position in SYRE in Q1 2022 and held it in 4 quarters. The position peaked at $7.16M in Q3 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Walleye Capital reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 243,372 Spyre Therapeutics shares in Q4 2024, an estimated $7.16M.
  • Walleye Capital first reported a position in Spyre Therapeutics in Q1 2022 and held it in 4 quarters.
  • Walleye Capital's Spyre Therapeutics position peaked at $7.16M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.